DBV Technologies S.A.

DBV Technologies S.A. is a French biopharmaceutical company specializing in the research and development of innovative treatments for food allergies and other immunological conditions. The company is best known for its proprietary Viaskin technology, a non-invasive patch platform designed to administer allergens or antigens directly to the intact skin, thereby reducing the risk of adverse systemic reactions. This approach aims to 're-educate' the immune system and offers a promising alternative for allergy management, particularly for pediatric patients who often lack other effective therapies. DBV Technologies has focused its efforts on pioneering therapies for peanut and cow’s milk allergies, with lead products including the Viaskin Peanut and Viaskin Milk patches. These products are undergoing rigorous clinical evaluation, with the Viaskin Peanut patch receiving Fast Track designation from the U.S. Food and Drug Administration due to its potential to address significant unmet medical needs in allergy treatment. The firm's clinical pipeline underscores its role as an innovator in therapeutic immunology, targeting a growing global health issue with the potential for broad clinical applications.